These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Acute exacerbation in antineutrophil cytoplasmic antibody-associated interstitial lung disease: Clinical features and risk factors. Otsuka J; Yoshizawa S; Ikematsu Y; Kudo K; Osoreda H; Ishimatsu A; Taguchi K; Moriwaki A; Wakamatsu K; Iwanaga T; Yoshida M Respir Med; 2022 Nov; 203():106992. PubMed ID: 36252462 [TBL] [Abstract][Full Text] [Related]
8. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. Yamaguchi K; Iwamoto H; Horimasu Y; Ohshimo S; Fujitaka K; Hamada H; Mazur W; Kohno N; Hattori N Respirology; 2017 Jul; 22(5):965-971. PubMed ID: 28198072 [TBL] [Abstract][Full Text] [Related]
9. Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases. Ba C; Wang H; Jiang C; Shi X; Jin J; Fang Q BMJ Open Respir Res; 2024 Feb; 11(1):. PubMed ID: 38413119 [TBL] [Abstract][Full Text] [Related]
10. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. Cao M; Sheng J; Qiu X; Wang D; Wang D; Wang Y; Xiao Y; Cai H BMC Pulm Med; 2019 Nov; 19(1):215. PubMed ID: 31727051 [TBL] [Abstract][Full Text] [Related]
11. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. Salonen J; Purokivi M; Bloigu R; Kaarteenaho R BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32265195 [TBL] [Abstract][Full Text] [Related]
12. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases. Salonen J; Vähänikkilä H; Purokivi M; Kaarteenaho R PLoS One; 2020; 15(11):e0242860. PubMed ID: 33253258 [TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end-products and receptor for advanced glycation end-products expression in patients with idiopathic pulmonary fibrosis and NSIP. Kyung SY; Byun KH; Yoon JY; Kim YJ; Lee SP; Park JW; Lee BH; Park JS; Jang AS; Park CS; Jeong SH Int J Clin Exp Pathol; 2014; 7(1):221-8. PubMed ID: 24427342 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease. Ba C; Jiang C; Wang H; Shi X; Jin J; Fang Q Ther Adv Respir Dis; 2024; 18():17534666241250332. PubMed ID: 38757948 [TBL] [Abstract][Full Text] [Related]
15. Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease. Adams CJ; Chohan K; Rozenberg D; Kavanagh J; Greyling G; Shapera S; Fisher JH Lung; 2021 Aug; 199(4):379-387. PubMed ID: 34347146 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease. Kono M; Miyashita K; Hirama R; Oshima Y; Takeda K; Mochizuka Y; Tsutsumi A; Miwa H; Miki Y; Hashimoto D; Suda T; Nakamura H Respir Med; 2021 Sep; 186():106534. PubMed ID: 34260978 [TBL] [Abstract][Full Text] [Related]
18. Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study. Zhai L; Wang Z; Yu W Ther Adv Respir Dis; 2024; 18():17534666241276800. PubMed ID: 39235441 [TBL] [Abstract][Full Text] [Related]
19. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis. Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ Front Immunol; 2023; 14():1189257. PubMed ID: 37409127 [TBL] [Abstract][Full Text] [Related]